MadameOvary.com Emphasizes Safety & Efficacy of Low-Dose Transdermal Hormone Therapy for Post-Menopausal Women

Low-dose transdermal estrogen therapy remains viable and safe

NEW HAVEN, Conn.--()--As the North American Menopause Society (NAMS) recently re-evaluated their position statement on the safety and efficacy of hormone therapy for vasomotor symptoms, MadameOvary.com, a site dedicated to helping women best understand their changing postmenopausal bodies, further stresses the viability and effectiveness of low-dose transdermal estrogen therapy.

“The risk/reward of postmenopausal hormone therapy (HT) continues to be greatly misunderstood by women, leaving them confused and overwhelmed by their options. Many will opt to suffer silently with symptoms like night sweats, hot flashes, and vaginal dryness”

“The risk/reward of postmenopausal hormone therapy (HT) continues to be greatly misunderstood by women, leaving them confused and overwhelmed by their options. Many will opt to suffer silently with symptoms like night sweats, hot flashes, and vaginal dryness,” says Mary Jane Minkin, MD, Clinical Professor of Obstetrics & Gynecology at Yale University and Founder of MadameOvary.com. “While appropriate and safe treatment should be individualized for each woman’s needs and risk profile, there are newer options with data showing lower risks of blood clot and stroke.”

Hormones used in HT can be delivered by a variety of methods, most often orally or transdermally. Oral estrogen undergoes first-pass metabolism through the liver, whereas transdermal estrogen does not. As a result, transdermally-administered estrogen can be given at lower doses and has a steadier release than oral estrogen; in addition to improving symptoms of vaginal pain and dryness which likely boosts overall sexual health, transdermally-administered estrogen may help to avoid mood swings, migraines, and fatigue.

The FDA recommends the lowest effective dose with any estrogen therapy for the shortest amount of time to achieve a woman’s personal treatment goals while the North American Menopause Society (NAMS) states that estrogen may be used at an appropriate dose and duration as determined by a woman’s healthcare provider. With a premeasured topical transdermal gel like Divigel, women can be assured their dosages are precise and accurate; this also makes it easier to adjust a given dosage.

Additionally, according to literature reviewed by Dr. Minkin in the Journal of Reproductive Medicine, the addition of transdermal estrogen in postmenopausal women with hypertension does not raise blood pressure and may help to lower it.

“Estrogen becomes a top priority for many women as they realize the potential to relieve post-menopausal symptoms, and as a possible result, improve sexual health. It’s vital to continue educating consumers on options available and dispel ongoing myths about hormone therapy,” adds Dr. Minkin.

Contacts

For Madame Ovary
Jaimie Weiner, 646-964-4446
jaimie@gcomworks.com

Release Summary

MadameOvary.com further stresses the viability and effectiveness of low-dose transdermal estrogen therapy.

MadameOvary.com